On this page
Clobetasol propionate
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Clobetasol Propionate | .5 mg/g | 861490 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 075027-001 | CLOBETASOL PROPIONATE | GEL | CLOBETASOL PROPIONATE | Prescription | AB | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 5 | Labeling | Approved | November 28, 2007 | — |
| Supplement | 4 | Labeling | Approved | December 20, 2000 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | December 20, 2000 | — |
| Supplement | 2 | Labeling | Approved | July 24, 2000 | — |
| Original application | 1 | Approved | October 31, 1997 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251008). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Clobetasol Propionate Gel, 0.05% is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply a thin layer of Clobetasol Propionate Gel, 0.05% to the affected skin areas twice daily and rub in gently and completely (see INDICATIONS AND USAGE ). Clobetasol Propionate Gel, 0.05% is a super-high potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Clobetasol Propionate Gel, 0.05% should not be used with occlusive dressings.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Clobetasol Propionate Gel, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In a controlled trial with clobetasol propionate gel, 0.05%, the only reported adverse reaction that was considered to be drug related was a report of burning sensation (1.8% of treated patients). In larger controlled clinical trials with other clobetasol propionate formulations, the most frequently reported adverse reactions have included burning, stinging, irritation, pruritus, erythema, folliculitis, cracking and fissuring of the skin, numbness of fingers, skin atrophy, and telangiectasia (all less than 2%). Cushing’s syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. The following additional local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with super-high potency corticosteroids such as Clobetasol Propionate Gel, 0.05%. These reactions are listed in approximate decreasing order of occurrence: dryness, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria.
Description
openFDA Drug LabelingDESCRIPTION Clobetasol Propionate Gel, 0.05% contains the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Chemically, clobetasol propionate is (11ß,16ß)-21-chloro-9-fluoro-11-hydroxy-16- methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione, and it has the following structural formula: Clobetasol propionate has the empirical formula C 25 H 32 ClFO 5 and a molecular weight of 467. It is a white to cream-colored crystalline powder insoluble in water. Clobetasol Propionate Gel, 0.05% contains clobetasol propionate 0.5 mg/g in a base of carbomer homopolymer type B, propylene glycol, purified water, and sodium hydroxide. structural_formula
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied Clobetasol Propionate Gel, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Clobetasol Propionate Gel, 0.05% is available as follows: 15 g tube (NDC 72162-1438-2) 30 g tube (NDC 72162-1438-3) 60 g tube (NDC 72162-1438-6) Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CLOBETASOL PROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-8637-1 | 63629-8637 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8637-1) / 15 g in 1 TUBE | July 30, 2008 |
| 63629-8638-1 | 63629-8638 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8638-1) / 30 g in 1 TUBE | November 11, 2008 |
| 63629-8639-1 | 63629-8639 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8639-1) / 60 g in 1 TUBE | July 31, 2008 |
| 72162-1438-2 | 72162-1438 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1438-2) / 15 g in 1 TUBE | August 16, 2023 |
| 72162-1438-3 | 72162-1438 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1438-3) / 30 g in 1 TUBE | August 16, 2023 |
| 72162-1438-6 | 72162-1438 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1438-6) / 60 g in 1 TUBE | August 16, 2023 |
| 0168-0293-15 | 0168-0293 | E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | 15 g in 1 TUBE (0168-0293-15) | February 15, 2000 |
| 0168-0293-30 | 0168-0293 | E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | 30 g in 1 TUBE (0168-0293-30) | February 15, 2000 |
| 0168-0293-60 | 0168-0293 | E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | 60 g in 1 TUBE (0168-0293-60) | February 15, 2000 |
| 45802-925-14 | 45802-925 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-925-14) / 15 g in 1 TUBE | July 30, 2008 |
| 45802-925-94 | 45802-925 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-925-94) / 30 g in 1 TUBE | November 11, 2008 |
| 45802-925-96 | 45802-925 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-925-96) / 60 g in 1 TUBE | July 31, 2008 |
| 51672-1294-1 | 51672-1294 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1294-1) / 15 g in 1 TUBE | May 28, 1999 |
| 51672-1294-2 | 51672-1294 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1294-2) / 30 g in 1 TUBE | May 28, 1999 |
| 51672-1294-3 | 51672-1294 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1294-3) / 60 g in 1 TUBE | May 28, 1999 |
| 63629-8637 | 63629-8637 | Bryant Ranch Prepack | — | July 30, 2008 |
| 63629-8638 | 63629-8638 | Bryant Ranch Prepack | — | July 30, 2008 |
| 63629-8639 | 63629-8639 | Bryant Ranch Prepack | — | July 30, 2008 |
| 72162-1438 | 72162-1438 | Bryant Ranch Prepack | — | July 30, 2008 |
| 0168-0293 | 0168-0293 | E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | — | February 15, 2000 |
| 45802-925 | 45802-925 | Padagis Israel Pharmaceuticals Ltd | — | July 30, 2008 |
| 51672-1294 | 51672-1294 | Sun Pharmaceutical Industries, Inc. | — | May 28, 1999 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.